

Technical considerations and the Economics of TAVR

Andrew J. Sampson MD
SVMG Interventional Cardiologist
Indiana ACC 10.13.2018

Disclosures

Medtronic--Consulting

TECHNICAL CONSIDERATIONS FOR TAVR


TF > Subclavian (if no LIMA) > Carotid > Trans-apical > Trans-caval

RBBB → higher implant, consider screw in pacing lead from subclavian

PCI to severe proximal large vessels

Coronary protection with guideliner/stents

Coronary protection



TAVR Economics

Can we afford to offer TAVR??

As TAVR continues to evolve, initial clinical benefits are now coupled with favorable economics


TAVR has matured from costly/risky procedure to one that saves lives and money for majority of patients with severe AS

Verdict is still out on the economic benefits in low risk population -- but appears promising

TAVR economics in the intermediate risk population

S3i Economics


Index Hospital Costs



Similar to the PARTNER 2A trial, procedural costs

S3i Economics


Total 1-Year Costs



Cost effectiveness in the intermediate risk population

S3i Economics

S3-TAVR vs. SAVR: Cost-Effectiveness



* Costs and benefits discounted at 3%